HX15001
/ Helixon Biotechnology (Suzhou)
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 18, 2026
A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
January 31, 2026
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HX15001 Injection in Healthy Chinese Subjects
(ChiCTR)
- P1 | N=30 | Not yet recruiting | Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Second Affiliated Hospital of Guangzhou Medical University
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 2
Of
2
Go to page
1